Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does OSIMERTINIB Cause Electrocardiogram qt prolonged? 181 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 181 reports of Electrocardiogram qt prolonged have been filed in association with OSIMERTINIB (TAGRISSO). This represents 0.7% of all adverse event reports for OSIMERTINIB.

181
Reports of Electrocardiogram qt prolonged with OSIMERTINIB
0.7%
of all OSIMERTINIB reports
30
Deaths
77
Hospitalizations

How Dangerous Is Electrocardiogram qt prolonged From OSIMERTINIB?

Of the 181 reports, 30 (16.6%) resulted in death, 77 (42.5%) required hospitalization, and 32 (17.7%) were considered life-threatening.

Is Electrocardiogram qt prolonged Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for OSIMERTINIB. However, 181 reports have been filed with the FAERS database.

What Other Side Effects Does OSIMERTINIB Cause?

Death (10,423) Malignant neoplasm progression (2,920) Diarrhoea (1,408) Drug resistance (1,026) Fatigue (819) Rash (772) Decreased appetite (706) Drug ineffective (627) Dyspnoea (621) Nausea (610)

What Other Drugs Cause Electrocardiogram qt prolonged?

QUETIAPINE (1,869) OLANZAPINE (1,325) RIBOCICLIB (1,020) AMIODARONE (1,000) HYDROXYCHLOROQUINE (992) CLOZAPINE (958) CITALOPRAM HYDROBROMIDE (917) ESCITALOPRAM OXALATE (899) ONDANSETRON (881) BUPROPION (853)

Which OSIMERTINIB Alternatives Have Lower Electrocardiogram qt prolonged Risk?

OSIMERTINIB vs OSPEMIFENE OSIMERTINIB vs OSPHENA OSIMERTINIB vs OVINE DIGOXIN IMMUNE FAB OSIMERTINIB vs OXACILLIN OSIMERTINIB vs OXALIPLATIN

Related Pages

OSIMERTINIB Full Profile All Electrocardiogram qt prolonged Reports All Drugs Causing Electrocardiogram qt prolonged OSIMERTINIB Demographics